8th German Pharm-Tox Summit

A mutation in the Btk SH2 domain, known to mediate ibrutinib resistance in chronic lymphocytic leukemia, causes a significant increase in kinase function by enhancing its binding affinity to regulatory proteins or peptides

Cancer pharmacology	

Cancer pharmacology and treatment

Oral presentation

Signal transduction and second messengers		 	

Identification of constituents conveying signals from MYD88L265P and CXCR4 or CXCR4-WHIM mutants leading to enhanced malignancy of Waldenstrom macroglobulinemia

<B>Posters will be presented during the time period mentioned above. This will give all participants and the poster jury the opportunity to interact with the presenting authors. Please be available to answer questions at your poster during the poster session. </B>


Session 2

Poster

Immunopharmacology / inflammation / anti-infectives	

Short talks

Martin Wist

Vortrag

Weitere Beteiligungen